- Revolution Medicines shares promising data around KRAS drug combinationRevolution Medicines on Thursday gave a first look at the early-stage data that led it to plan a Phase 3 trial combining two KRAS drugs in pancreatic cancer. One of the two drugs is a ...Endpoints · 24d ago↗ source
- A PureTech startup banks $180M for a new IPF drug<figure><div><img src="https://imgproxy.divecdn.com/KuEcOh78IgcBW2NsJQndhSsRzY-l5rCzAaiUoHZ7Exg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMDkwODIwMzkwLmpwZ…BioPharma Dive · 24d ago↗ source
- Otsuka reports long-term kidney data key to Voyxact's bid for full approvalOtsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease. The company said the Phase 3 study showed Voyxact stabil…